Wegovy’s supply + brewing competition concerns overshadow a decent Q2
04/08/22 -"In Q2, Novo continued its strong run, driven by strong growth momentum seen in both Obesity and GLP-1 Diabetes franchise. However, emerging and potential competition from Eli Lilly’s Mounjaro in ..."
Pages
65
Language
English
Published on
04/08/22
You may also be interested by these reports :
17/08/22
In the Q2 Lundbeck continued its solid top-line momentum, driven by strong growth seen in the main-marketed drugs. However, lower profitability due ...
17/08/22
Zantac and Biden seem to have taken the wind from even the strongest pharma groups’ sails with the sector being the worst performer last week and ...
16/08/22
To factor in the negative investor sentiment regarding the potential adverse implications of the Zantac trial in the US (expected to start by end-Aug ...
16/08/22
2Q/1H22: Strong cash position and pipeline prioritization